^
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
BRCA1 mutation
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Onbevzi (bevacizumab biosimilar)
Sensitive: A1 - Approval
BRCA1 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
HRD
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
BRCA1 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
HRD
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
BRCA1 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
BRCA1 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
MSI-H/dMMR
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
BEP
Sensitive: A2 - Guideline
TMB-H
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
EP
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
VAC
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
IP
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
sorafenib
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
topotecan
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
etoposide oral
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
trametinib
Sensitive: A2 - Guideline
NTRK3 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Peritoneal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Peritoneal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Peritoneal Cancer
entrectinib
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
fulvestrant
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
megestrol
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
pazopanib
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
bevacizumab + niraparib
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
pemetrexed
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
melphalan
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
cisplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
tamoxifen
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
leuprolide acetate
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
exemestane
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
letrozole
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
anastrozole
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
OMP-305B83
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Peritoneal Cancer
STRO-002
Sensitive: B - Late Trials
PD-L1 expression
Peritoneal Cancer
pembrolizumab
Sensitive: C1 - Off-label
HRD + BRCA1 mutation
Peritoneal Cancer
niraparib
Sensitive: C3 – Early Trials
HRD + BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive: C3 – Early Trials
TUBB3 expression
Peritoneal Cancer
bevacizumab + ixabepilone
Resistant: C3 – Early Trials